About this trial
A Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
Patient Profile
This trial is for patients with High-Risk Muscle-Invasive Bladder Cancer Who are ctDNA Positive Following Cystectomy (IMvigor011)
Where’s this trial being run?
Cork University Hospital, Tallaght University Hospital, and St Vincents University Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | IMvigor011 B042843 |
|---|---|
| Number: | 21-38 |
| Full Title: | A Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy |
| Principal Investigator: | Prof Ray McDermott |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | ROCHE |
| Recruitment Started: |
Global: May 2021 Ireland: December 2021 |
| Global Recruitment Target: | 495 |
|---|---|
| Ireland Recruitment Target: | 9 |